trial

Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects

NCTId NCT00567034
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 30 (actual)
Sponsored by Mclean Hospital
Primary completion 2010-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
30 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2006-12
Primary completion
2010-12
Eligibility
ALL · 21 Years · 55 Years

Interventions & indications

Drugs
Naltrexone

Sponsors

Mclean HospitalLead Sponsor

Investigators

1
Igor Elman, M.D.Principal Investigator

Sites

1 total
Belmont, United States

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE1
Primary Completion Date
2010-12
Status
COMPLETED
relationships
The graph out of here
drug
Naltrexone
drug
lead_sponsor
Mclean Hospital
company
indication
Psychotic Disorders
indication
Pain
indication
Metabolic Syndrome
indication
investigator
Igor Elman, M.D.
person